SUB1

Activated RNA polymerase II transcriptional coactivator p15 · P53999 · SUB1 on Sugi Atlas →

0 patent compounds predicted against SUB1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SUB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Vorinostat in Children PHASE1/PHASE2COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors PHASE1WITHDRAWN
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia nanCOMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex nanENROLLING_BY_INVITATION
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. nanUNKNOWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction nanCOMPLETED
Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients With HIV-1 nanNOT_YET_RECRUITING
Immune Interactions in Severe Asthma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SUB1 binder may also engage these)

ProteinNameSimilarity
Q4R947 1.000 Q4R947 →
Q5R6D0 1.000 Q5R6D0 →
Q5ZK63 0.997 Q5ZK63 →
Q63396 0.994 Q63396 →
P11031 0.993 P11031 →
Q5BJU6 0.921 Q5BJU6 →
Q642H2 0.918 Q642H2 →
Q32M00 0.916 Q32M00 →
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 0.913 landscape →
Q0VD32 0.913 Q0VD32 →
P60762 0.913 P60762 →
O60519 0.913 O60519 →
MORF4L1 Mortality factor 4-like protein 1 0.911 landscape →
A5GFS8 0.909 A5GFS8 →
Q5RA82 0.909 Q5RA82 →
Q61187 0.907 Q61187 →
Q5ZJV7 0.907 Q5ZJV7 →
Q6IRE4 0.906 Q6IRE4 →
O77768 0.905 O77768 →
A4IGK3 0.905 A4IGK3 →
Q08DJ0 0.905 Q08DJ0 →
Q5RCB7 0.905 Q5RCB7 →
Q6AYU1 0.905 Q6AYU1 →
VAPB Vesicle-associated membrane protein-associated protein B/C 0.905 landscape →
Q5XIT1 0.905 Q5XIT1 →
DNMT3A DNA (cytosine-5)-methyltransferase 3A 0.904 landscape →
Q9NP50 0.904 Q9NP50 →
Q6PER3 0.904 Q6PER3 →
Q5NVP9 0.903 Q5NVP9 →
Q9Z204 0.903 Q9Z204 →